462 related articles for article (PubMed ID: 28303769)
1. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
[TBL] [Abstract][Full Text] [Related]
2. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
4. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
5. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
6. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
7. Combination therapies utilizing neoepitope-targeted vaccines.
Lee KL; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2021 Apr; 70(4):875-885. PubMed ID: 33033852
[TBL] [Abstract][Full Text] [Related]
8. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
9. Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy.
Wilson EA; Anderson KS
Expert Rev Proteomics; 2018 Dec; 15(12):1065-1077. PubMed ID: 30408427
[TBL] [Abstract][Full Text] [Related]
10. The immunoinformatics of cancer immunotherapy.
Deluca DS; Blasczyk R
Tissue Antigens; 2007 Oct; 70(4):265-71. PubMed ID: 17767547
[TBL] [Abstract][Full Text] [Related]
11. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
[TBL] [Abstract][Full Text] [Related]
12. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
Liu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
[TBL] [Abstract][Full Text] [Related]
13. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
[TBL] [Abstract][Full Text] [Related]
14. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
15. MHC-binding peptides as immunotherapeutics for cancer.
Kobayashi H; Kennedy R; Lu J; Davila E; Celis E
Immunol Invest; 2000 May; 29(2):105-10. PubMed ID: 10854176
[No Abstract] [Full Text] [Related]
16. Immunization with short peptide particles reveals a functional CD8
He X; Zhou S; Dolan M; Shi Y; Wang J; Quinn B; Jahagirdar D; Huang WC; Tsuji M; Pili R; Ito F; Ortega J; Abrams SI; Ebos JML; Lovell JF
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34862254
[TBL] [Abstract][Full Text] [Related]
17. The neoepitope landscape of breast cancer: implications for immunotherapy.
Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
[TBL] [Abstract][Full Text] [Related]
18. Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.
Valmori D; Lévy F; Godefroy E; Scotto L; Souleimanian NE; Karbach J; Tosello V; Hesdorffer CS; Old LJ; Jager E; Ayyoub M
Clin Immunol; 2007 Feb; 122(2):163-72. PubMed ID: 17064965
[TBL] [Abstract][Full Text] [Related]
19. Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?
Lutz ER; Jaffee EM
Cancer Immunol Res; 2014 Jun; 2(6):518-21. PubMed ID: 24795140
[No Abstract] [Full Text] [Related]
20. Adding fuel to the fire: immunogenic intensification.
O'Sullivan Coyne G; Gulley JL
Hum Vaccin Immunother; 2014; 10(11):3306-12. PubMed ID: 25483630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
